IMS Health Total Sales Audit (TSA) has stated that the Indian pharmaceutical market has clocked a growth of 8.9 per cent during the month of June 2013. The market has remained fairly static for the month of June 2013 as compared to previous month. The strong onset of monsoons across the country, which saw acute therapies (respiratory, gastro-intestinals, anti-infectives and pain) soar, was offset to some extent by the subdued reaction from the trade to DPCO 2013 announcement.

Product impacted by this regulation experienced a dip in primary purchases and stockings – which was also seen in the previous month. A survey of stockists conducted by IMS Health revealed that 40 per cent of respondents had incomplete knowledge about DPCO 2013 and its implication. Clarity is still an issue particularly in North India, followed to some extent in East India. While GlaxoSmithKline (GSK) climbed up two ranks in June as compared to the previous month, Ranbaxy has dropped two ranks down; ranks of other corporations remained unchanged. For the June, local companies have grown almost twice by 10.2 per cent as compared to MNCs at 5.5 per cent.

During the June 2013, Respiratory segment has overtaken anti-diabetics as the fastest growing therapy with growth of 22.8 per cent followed by anti diabetic by 15.1 per cent and gastro intestinal at 9.8 per cent. Led by the strong onset of monsoons all across the contry, acute therapies grew almost at part with chronic segment. Acute therapies contributed 71 per cent to total with growth of 8.8 per cent and chronic therapies contributed 29 per cent with growth of nine per cent. Phensedyl Cough brand generated highest sales of Rs.24.9 crore during June 2013 and was followed by Human Mixtard 30/70 with sales of Rs.21.6 crore, Corex (Rs.21.5 crore), Voveran (Rs.21.4 crore) and Dexorange (Rs.19.9 crore) respectively.

IMS Health pointed out that the market will recover over the next few months, as issues around market regulations (DPCO 2013, pioglitazone ban) clear, and register a FY 2013 growth between 11-13 per cent as forecasted by the IMS market Prognosis report.

The pharmaceutical market for the period MAT June 2013, improved by 10 per cent to Rs.74,656 crore. Abbott remained on top position with sales of Rs.5,173 crore and followed by Cipla (Rs.3,641 crore), Sun Pharmaceutical (Rs.3,318 crore), GlaxoSmithKline (Rs.3,035 crore) and Zydus Cadila (Rs.2,938 crore) respectively.